NASDAQ · ACHV
Achieve Life Sciences, Inc.
$7.19+$0.34 (+4.96%)
Achieve Life Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.78% below the high.
Loading market information…
NASDAQ · LFCR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Lifecore Biomedical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.39% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Lifecore Biomedical, Inc.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of -$0.30. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Lifecore Biomedical, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2025 | Apr 3, 2025 | -$0.47-235.71% vs estimate | $35.15M+5.73% vs estimate |
|---|
| Q2 2025 | Jan 2, 2025 | -$0.25+7.41% vs estimate | $32.56M+9.47% vs estimate |
|---|
| Q1 2025 | Oct 4, 2024 | -$0.49-6.52% vs estimate | $24.71M+6.54% vs estimate |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $6.39.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.19+$0.34 (+4.96%)
Achieve Life Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.78% below the high.
$9.57+$0.33 (+3.57%)
Sight Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.47% below the high.
$8.09+$0.23 (+2.93%)
Alpha Teknova, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.66% below the high.
$0.68+$0.00 (+0.46%)
Canopy Growth Corporation’s quoted price sits in the lower half of its reported 52-week range, 71.64% below the high.
$4.08$0.00 (0.0%)
Aurora Cannabis Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.85% below the high.
$5.94$0.00 (0.0%)
BioAge Labs Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.12% below the high.
$2.68+$0.22 (+8.94%)
Owens & Minor, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.75% below the high.
$1.44+$0.03 (+2.13%)
ProQR Therapeutics N.V.’s quoted price sits in the lower half of its reported 52-week range, 48.75% below the high.
